Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CLDN18.2 positive

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	IBI-343 Sensitive: B - Late Trials IBI-343 Sensitive : B	IBI-343 Sensitive: B - Late Trials IBI-343 Sensitive : B
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2
CLDN18.2 positive	Pancreatic Ductal Adenocarcinoma	CLDN18.2 positive	Pancreatic Ductal Adenocarcinoma	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2
CLDN18.2 positive	Solid Tumor	CLDN18.2 positive	Solid Tumor	MIL93 Sensitive: C2 – Inclusion Criteria MIL93 Sensitive : C2	MIL93 Sensitive: C2 – Inclusion Criteria MIL93 Sensitive : C2
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	AB011 Sensitive: C2 – Inclusion Criteria AB011 Sensitive : C2	AB011 Sensitive: C2 – Inclusion Criteria AB011 Sensitive : C2
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	AZD0901 Sensitive: C2 – Inclusion Criteria AZD0901 Sensitive : C2	AZD0901 Sensitive: C2 – Inclusion Criteria AZD0901 Sensitive : C2
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	AZD0901 Sensitive: C2 – Inclusion Criteria AZD0901 Sensitive : C2	AZD0901 Sensitive: C2 – Inclusion Criteria AZD0901 Sensitive : C2
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	AB011 Sensitive: C3 – Early Trials AB011 Sensitive : C3	AB011 Sensitive: C3 – Early Trials AB011 Sensitive : C3
CLDN18.2 positive	Pancreatic Cancer	CLDN18.2 positive	Pancreatic Cancer	ZL-1211 Sensitive: C3 – Early Trials ZL-1211 Sensitive : C3	ZL-1211 Sensitive: C3 – Early Trials ZL-1211 Sensitive : C3
CLDN18.2 positive	Gastric Adenocarcinoma	CLDN18.2 positive	Gastric Adenocarcinoma	zolbetuximab-clzb Sensitive: C3 – Early Trials zolbetuximab-clzb Sensitive : C3	zolbetuximab-clzb Sensitive: C3 – Early Trials zolbetuximab-clzb Sensitive : C3
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	ZL-1211 Sensitive: C4 – Case Studies ZL-1211 Sensitive : C4	ZL-1211 Sensitive: C4 – Case Studies ZL-1211 Sensitive : C4
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	CLDN18.2-targeted CAR-T immunotherapy Sensitive: D – Preclinical CLDN18.2-targeted CAR-T immunotherapy Sensitive : D	CLDN18.2-targeted CAR-T immunotherapy Sensitive: D – Preclinical CLDN18.2-targeted CAR-T immunotherapy Sensitive : D
CLDN18.2 positive	Pancreatic Cancer	CLDN18.2 positive	Pancreatic Cancer	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical CLDN18.2-targeted antibody-drug conjugate Sensitive : D	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical CLDN18.2-targeted antibody-drug conjugate Sensitive : D